Data for SemBioSys' insulin to be presented at the American Diabetes Association's 69th Scientifi...( CALGARY June 5 / SemBioSys Genetics I...)

CALGARY, June 5 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, today announced that it will present the recent results of the Phase I/II study with its biosimilar human insulin in a late-breaking scientific poster at the American Diabetes Association's (ADA) 69th Scientific Sessions in New Orleans. The poster presentation will take place at the Morial Convention Center Poster Hall E on Sunday, June 7th and is entitled: "Analytical Characterization, Safety and Clinical Bioequivalence of Recombinant Human Insulin from Transgenic Plants," by Joseph Boothe and colleagues. The abstract for the presentation is available via the ADA website at http://ww2.aievolution.com/ada0901/index.cfm?do=abs.viewAbs&abs=7845.

The poster presentation details the clinical trial results of SemBioSys' first "in-man" clinical study of SBS-1000, a recombinant human insulin manufactured using the Company's proprietary platform, which allows for highly scalable, low cost production. The trial demonstrated that SBS-1000 was bioequivalent to Eli Lilly's Humulin(R) R, a widely-used human insulin in North America, with the expected safety profile. Additionally, SBS-1000 in humans showed pharmacokinetics and pharmacodynamics indistinguishable from Humulin(R) R and was well tolerated at pharmacologically active dosages. SemBioSys plans to publish the complete clinical trial results in a scientific journal in the near future.

About SemBioSys

Calgary, Alberta-based SemBioSys is a world leader in manufacturing high-value proteins and oils in plant seeds. With its unique, proprietary platform, SemBioSys provides partners with product enablement, exceptionally low cost and unprecedented scalability. The Company applies this platform with high selectivity to oppor
'/>"/>